%0 Journal Article
%T 吉非替尼治疗非小细胞肺癌进展<br>Progress of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
%A 达德转
%A 潘志昂
%A 李林俞
%A 李红玲
%J Advances in Clinical Medicine
%P 6150-6155
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1112913
%X 在世界范围内恶性肿瘤中死亡率最高的是肺癌，其中非小细胞肺癌(NSCLC)占80%以上。而我国是肺癌大国，绝大多数肺癌患者都诊断于中晚期，失去最佳手术机会，中晚期肺癌患者仍以放化疗及分子靶向治疗为主。吉非替尼是用于NSCLC临床治疗的代表性分子靶向药物，然而分子靶向药吉非替尼在临床应用中仍存在耐药现象，严重影响分子靶向药物治疗肺癌患者的疗效。因此探索吉非替尼的耐药机制，寻找耐药的分子标志物对治疗NSCLC有重要意义。本文将对吉非替尼靶向治疗NSCLC的最新进展进行总结。<br />
Lung cancer has the highest mortality rate among malignant tumors worldwide, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. While China is a big country with lung cancer, the vast majority of lung cancer patients are diagnosed in the middle and advanced stage, losing the best opportunity for surgery. Patients with middle and advanced stage lung cancer are still mainly treated with radiotherapy and chemotherapy and molecular targeted therapy. Gefitinib is a representative molecular targeted drug used in the clinical treatment of NSCLC. However, drug resistance of the molecular targeted drug still exists in clinical application, which seriously affects the efficacy of molecular targeted drugs in the treatment of lung cancer patients. Therefore, it is of great significance to explore the mechanism of gefitinib resistance and to find the molecular markers of resistance for the treatment of NSCLC. This article will summarize the latest progress of gefitinib targeted therapy for NSCLC.
%K 吉非替尼，非小细胞肺癌(NSCLC)，耐药机制<br>Gefitinib
%K Non-Small Cell Lung Cancer (NSCLC)
%K Resistance Mechanisms
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=47646